Table 2.
Differences of established subtypes and clinical stages for DCE-MRI subtypes in the imaging-subtype discovery cohort. The relationships between three imaging subtypes and established subtypes of BC, including clinical receptor-based, IHC-based and PAM50-based subtypes, as well as the clinical stages, were calculated.
| Factors | Subtype 1 (n = 50) |
Subtype 2 (n = 62) |
Subtype 3 (n = 62) |
p-Value |
|---|---|---|---|---|
| ER status | 0.011 a | |||
| ER positive | 44 | 39 | 44 | |
| ER negative | 6 | 23 | 18 | |
| PR status | 0.109 a | |||
| PR positive | 37 | 34 | 40 | |
| PR negative | 13 | 28 | 22 | |
| HER2 status | 0.409 a | |||
| HER2 positive | 10 | 16 | 10 | |
| HER2 negative | 40 | 46 | 52 | |
| Ki67 status | 0.004 a | |||
| Ki67 high | 31 | 54 | 51 | |
| Ki67 low | 19 | 8 | 11 | |
| IHC-based subtype | 0.051 b | |||
| Luminal-A | 13 | 6 | 9 | |
| Luminal-B | 31 | 34 | 36 | |
| HER2-positive | 3 | 8 | 4 | |
| Triple-negative | 3 | 14 | 13 | |
| PAM50 subtype | 0.005 b | |||
| Luminal-A | 19 | 12 | 18 | |
| Luminal-B | 11 | 19 | 13 | |
| HER2-Enriched | 6 | 16 | 7 | |
| Basal-like | 7 | 15 | 21 | |
| Normal-like | 7 | 0 | 3 | |
| Pathological stage | <0.001 a | |||
| Stage I | 28 | 16 | 14 | |
| Stage II | 19 | 36 | 39 | |
| Stage III | 3 | 13 | 9 |
Note: unless otherwise indicated, data are number of patients or the p-value of the statistical test. a p-value for the two-sided Pearson’s chi-squared test, b p-value for the two-sided Fisher’s exact test.